Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
With the change of name, trading ID and shortly to come consolidation of 100 shares to 1 next week, can we expect a turning point here at Falanx ? The Chairman's report put a positive spin on recent trading but is it 'spin' ?
As a LTH, I've seen numerous statements from CEO Mike Read foretelling good news just round the corner and added around .07p mark to my long-term holding bought at much higher rates substantially improving my buying average. Earlier this year there were sizeable buys from the Board at 1p - 1.25p - quite a substantial percentage difference. Now, following a consolidation, the shares could see more selling. I've seen with other consolidations, prior to the consolidation taking effect there is effectively no realistic market as the spread becomes too wide - this has clearly been the case with Falanx. Following other consolidations, I can think of RENE or VOG two cases which immediately come to mind, trades become available again and large holders have used it as their exit point at the expense of small holders.
Is this now a turning point for Falanx ?
For the good at last ?
Or more failure ?
I'm a very long term holder in Futura and seen the price gyrate to 90p down to 6p I recall - over the years one could have traded this very profitably as it swung back and forth, never quite holding on to its peaks for any decent period and to some extent never lingered too long in the troughs either. I recall the Daily Mail article 9th September 2016 headlined: "Viagra too slow for you ? Now for the gel that works in 5 mins" and the implication was a market launch in less than 2 years.
Here we are over 6 years later and we're teasingly told that sales can be expected later 1st half 2023.
Slowly, slowly the publicity machine is being geared up with the briefest of details as to contracts signed, manufacturing dates as James Barder says that can't say too much because of commercial sensitivities ! It seems to me that the BoD has decided all must wait on the FDA final approval to allow over the counter sales in the US. Too many positives have already been released about the work done on submitting 'full dossiers' to the FDA, about the conformity of meeting all of its requirements to counteract any likelihood of now not being approved by the FDA.
We were told that the European/UK contract assigned to Coopers was only agreed after they had satisfied themselves fully that the product actually worked to their satisfaction.
The sp has now moved back to a place I believe will stabilise awhile before moving slowly ever more forward. When the RNS is announced that the final approval from the FDA is given probably within the next 2 to 3 months, I feel sure that the sp could bust the £1 barrier and much will depend on the Board's management of publicity as to how far it will go upwards even before any sales take place.
Another Daily Mail headline like 2016 and anything is possible. And if the sales progress worldwide - I foresee they will self-generate from country to country as publicity feeds upon itself. At that point there will have been a hefty increase in the sp and shareholders can decide whether to take profits risk-free, or stay the course if they believe the product really is the gem that the two ED specialists appear to describe it - thanks to the link above from 'wearelallguessing'
https://www.futuramedical.com/investor-centre/videos-and-webcasts/videos/
Here's James Barder 's Proactive interview this morning just released. Looking for some new news - as The.Italian queried above in the previous post - at least Barder is smiling more this time :)
https://www.youtube.com/watch?v=AZ1uLC9XxPI
Today's RNS is mostly already well-known by us shareholders, but today's message has been dressed up well. I don't expect much further news until February - I don't know what others think. But it should keep the sp stable until then. Here's Proactive's take on the news:
https://www.proactiveinvestors.co.uk/companies/news/1001025/futura-medical-hails-progress-of-med3000-gel-1001025.html
Next Update critical - i wouldn't agree Ambers235 - unless you mean for us shareholders wellbeing - ie to get the sp where it should be - which in my opinion is above 3p.
You're right about their absence from Amazon - I hadn't spotted that. Whilst the margin loss from an Amazon sale is peanuts, that from a Boots or Lloyd is likely to be around 30 - 40%. Given that the current sale price is £45 + vat is not going to leave a lot to package/service the products but to my mind is the only way these products are going to sell. If they're as good as they think they are, MHC can afford a higher margin loss to get them off the ground initially.
Trustpilot reviews are now very low indeed and without volume, the % of bad to good reviewers is bound to go up and that will not look very good - take a look now and the negatives hit you in your face. Perhaps you're right Ambers235 - the Amazon change could suggest a retail link-up in the offing. I did get a marketing email a week back encouraging me to take up the Heart test but I'd sooner they got on with a retail move pronto.
I still have my holding in FLX and it's been years that they've promised jam tomorrow.
When will they learn that it's results that are needed - cut your costs until you can afford them (ie make a profit). I sense that at last they are closer to a profit position but consolidating the shares isn't the way forward. Better they die now rather than kid yet more backers that all will be well and then watch a 100 x shareprice dilute. As it stands right now, at sub 1p, they have all the impetus they need to perform.
Consolidate now and all that will happen is that they will be tempted to just sell more shares and/or borrow. Without the Company getting to grips with staff/management performance - it'll be a cop-out and end up with yet more shareholders dilution.
Great news HawaiifiveO - but I'm at a loss to know why the likes of Lombard Odier and Miles Pelham have been running down their holdings in recent weeks at such a low sp. Especially given that Woodbois' trading numbers continue to grow positively and the company is held in such high esteem with the President and senior cabinet ministers of Gabon.
Woodbois is supporting Gabon at the COP27 both promoting Carbon Credits for the country - and is making a start for itself too in a small way in this market.
It's one of those times when as a Private Investor, you can't do much but watch and be patient. Their current financial numbers are very good and trading forecasts continue on an upward trend - and if that wasn't enough, there is the Carbon Credits potential. GLA
For what it's worth, I met who I perceive to have excellent knowledge of the Company - I've mentioned this in the past - I can only say that they said 'stick with it'. Trouble is they don't see it as we do - an sp seemingly without friends - they see it as the Company is doing well.
So, for what it's worth, the message is: 'stick with it'.
Mornington-oz - I totally agree that the potential at Woodbois is huge - but for whatever reason Lombard Odier is downsizing it's holding and I'm assuming we'll have another TRN-1 shortly showing their new lower holdings.
The numbers from Woodboisr 3rd quarter trading were excellent and all the more so against the current world back-drop - I can only assume LO are raising funds for alternative investments given how widely is the current investing malaise which often throws up investing opportunities where shares have been oversold.
I would say though that Woodbois looks just like such an oversold share and/or investment opportunity ! For the time being though, I'm going to have to sit on my hands and be patient.
It was definitely £2000 for a course of treatment.
That number I heard him say when I was at an early share investors meeting probably around 2016/2017. Might have been in Westminster Hall when the big Investor Show was put on by Tom Winnifrith. Also, I think it is mentioned in the youtube that we all saw on this BB in 2020 when he used that number to show how the company would be worth x billions to a big Pharma.
Unfortunately, for reasons that I think none of us can truly interpret, we must await the FDA decision. Yes, I think it is a no-brainer and will be OK but the Barder has made such a meal of the FDA requirements he has built into his message unwittingly the possibility of failure - and that's what the market is not liking.
It's worth bearing in mind too that in Germany precautions against Covid have recently been toughened as the incidence of Covid infections rise: https://amp.dw.com/en/new-german-covid-19-rules-come-into-force-as-infections-rise-in-colder-months/a-63305695
"it's not for sale yet"
Burgerneck - welcome back - it must be a year or more since you last commented on FUM. For all that the BoD have us told shareholders in the meantime, not a lot has happened that we can actually see. So, you've not missed much. However, ever so slowly, like a turning tanker, initial sales progress is promised soon. Will it be outside of the US by the end of this year or do we await for the final approval by the US Food and Drug Administration which could be sometime in the 1st quarter 2003 ?
I'm looking at a Daily Mail article headed: "Viagra too slow for you ? Now for the gel that works in 5 Mins" which if I recall correctly, propelled the sp to above 90p. Trouble is that was published 9th September 2016 !
But as 81 Lucky posted recently:
"Eroxon will be a market disruptor, if not in US, then in rest of the world. It's a win/win"
I believe that to be true. GLA
Thanks for the link Jet7 - but their analysis is very lightweight & done to promote themselves. I do agree though the institutions - Lobard Odier in particular - will do really well if Eroxon is successful. By rights, FUM in a year's time should be a completely different company with royalties and/or license income from sales. Perhaps it's more likely they'll be bought out ?
I wonder though - are we risk-free now ? Why does it take so long to get FDA approval ? I guess this is the real hurdle we need to get over - all the others being just stepping-stones in comparison. Once over, the sp should really rocket. Is it conceivable the FDA could find a reason to decline permission for Over the Counter sales ? If the market weren't so weak, I would be tempted to sell up elsewhere and reinvest in FUM but . . . there's always a 'but' with AIM shares.
"The Covid cases are rising rapidly so our revenue will also."
I agree jamrock - had quite a few unrelated contacts going down with Covid (I'm in south-east) - and all had got through their free packs of LFTs and needing to frequently test to ensure they're not infecting others. So, now buying them in.
I wonder if on balance they are sellers - beechknot ? Yes the sp was weaker but not sufficient in my opinion if the large trades declared several hours late this afternoon were all sellers. Will there be a TR1 Monday/Tuesday from a large holder perhaps that might explain things better?
However, I'm hoping though, we'll see an RNS next week on 3rd quarter's trading. The earlier months have been excellent this year and as I haven't heard anything politically negative coming from Gabon, the results trend should continue to be good. GLA
I agree Doc - see Before & After images from CNN
https://edition.cnn.com/2022/09/30/us/hurricane-ian-sanibel-before-after/index.html
There's always someone worse off than oneself.
Thanks wpa5
Proactive has made the figures and position the company is in so much better. The headings are correct and if we were starting from here the picture would look immensely rosy. Of course I recognise we are now looking at it with the jaundiced view of hindsight.
The sp could turn substantially on commercial news and it's worth therefore continuing to hold in my opinion. GLA